Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination regimen consisting of **cisplatin** (a platinum-based chemotherapeutic agent), **vinblastine** (a vinca alkaloid antineoplastic), and **SHAO**. Cisplatin causes DNA crosslinking and apoptosis in rapidly dividing cells, while vinblastine inhibits microtubule formation, leading to mitotic arrest. The mechanism, identity, or function of "SHAO" is unknown based on provided data and standard databases. Cisplatin and vinblastine are used together in oncological settings, primarily for cancers such as testicular cancer, non-small-cell lung cancer, and urothelial carcinoma, but the specific combination with "SHAO" is not described in the medical literature[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cisplatin + vinblastine + SHAO.